Skip to main content

Anchored cAMP signalling - implications for treatment of human disease

Objective

Signalling pathways and networks involving the signal compound cAMP are involved in major chronic diseases within the European community such as HIV, cancer, diabetes type II, cardiovascular disease, and genetic diseases such as diabetes incipidus and muscular dystrophies. However, no systematic approach has explored the therapeutic potential in targeting the cAMP signal pathway in conditions such as listed above with a dysregulated cAMP signal pathway. The focus of the research in the present proposal is to devise and test of therapeutic strategies based on understanding function of components of signalling networks involving the signal compound cAMP, the down-stream effectors, interaction with targeting molecules, and substrates. Specifically, work will be aimed at solving highly competitive and major tasks by joint effort leading to in vivo proof of principle experiments and drug development.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY OF OSLO
Address
Sognvannsveien 9
0317 Oslo
Norway

Participants (9)

BIAFFIN GMBH & CO KG
Germany
Address
Universitaetstrasse 150
44870 Bochum
BIOLOG LIFE SCIENCE INSTITUTE, FORSCHUNGSLABOR UND BIOCHEMICA- VERTRIEB GMBH
Germany
Address
Flughafendamm 9A
28199 Bremen
FONDAZIONE TELETHON
Italy
Address
Via Prospero Santo Croce
00167 Roma
FORSCHUNGSVERBUND BERLIN E.V.
Germany
Address
4,Robert-roessle-strasse 10
13125 Berlin
GOETEBORG UNIVERSITY
Sweden
Address
9,Medicinaregatan 9
405 30 Goeteborg
INSTITUT CURIE
France
Address
Rue D'ulm 26
75248 Paris
LAURAS AS
Norway
Address
Gaustadalleen 21
0349 Oslo
UNIVERSITY OF GLASGOW
United Kingdom
Address
University Avenue
Glasgow
UNIVERSITY OF KASSEL
Germany
Address
Heinrich Piett Strasse, 40, Raum 2161
34132 Kassel